Akanda Announces Closing of Registered Direct Offering
Akanda, an international medical cannabis company trading on NASDAQ under the symbol AKAN, has closed its registered direct offering. The offering involved the sale of 2,491,381 common shares at $0.1031 per share and 21,756,922 pre-funded warrants at $0.103 per share. The warrants are immediately exercisable at $0.0001 per share. Univest Securities acted as the exclusive financial advisor. Gross proceeds were approximately $2.5 million, before deducting fees and expenses. Funds will be used for capital expenditures, working capital, corporate purposes, debt repayment, and acquisitions.
- Raised approximately $2.5 million in gross proceeds.
- Sale price of shares and pre-funded warrants adheres to Nasdaq’s minimum price rules.
- Immediate exercise option for pre-funded warrants at $0.0001 per share.
- Funds directed towards capital expenditures, working capital, corporate purposes, debt repayment, and acquisitions.
- Univest Securities acted as the exclusive financial advisor, providing expertise in the offering.
- Dilution of existing shares with issuance of 2,491,381 common shares and 21,756,922 pre-funded warrants.
- Potential further dilution if all pre-funded warrants are exercised.
- Net proceeds reduced by financial advisor fees and other offering expenses.
- Stock price set at a low $0.1031 per share, which might indicate undervaluation.
Insights
Akanda Corp.'s recent registered direct offering, raising approximately
From a financial perspective, securing funds at the minimum price allowed under Nasdaq rules indicates a strategic move to attract investors while maintaining compliance with regulatory standards. However, the pricing at
Investors should be cautious about the dilution effect on existing shares due to the large number of new shares and warrants issued. Such dilution could potentially affect the earnings per share (EPS) and the overall value of the stock in the short term. On the flip side, if the capital is deployed effectively, it may lead to enhanced operational capacity and long-term growth, thereby potentially offsetting the initial dilution impact.
The company’s plan to use proceeds for refinancing or repaying existing debt is a positive signal, indicating a focus on maintaining a healthier balance sheet. However, it’s imperative to monitor how these funds are actually utilized over the coming quarters to assess their impact on financial health and operational performance.
For investors, understanding the broader market context in which Akanda operates is crucial. The cannabis industry, particularly the medical segment, is experiencing significant regulatory and competitive shifts. Akanda's move to raise funds through a direct offering highlights the ongoing need for capital in this volatile market.
The issuance of pre-funded warrants is particularly interesting. These instruments provide investors the opportunity to buy shares at a nominal additional cost, which could be seen as an attractive feature. The immediate exercisability of these warrants may indicate confidence from both the company and the advisors in the demand for Akanda’s stock. However, it also implies that the company is willing to offer more favorable terms to secure the needed capital swiftly.
Given the stated use of proceeds—covering a broad range of operational needs—it’s essential for investors to track how these funds directly contribute to enhancing Akanda’s market position. If the capital is primarily used for growth and strategic acquisitions, it may lead to increased market share and competitive advantage. Conversely, if it is used more for sustaining current operations, it might indicate underlying financial pressures.
In the context of industry dynamics, such capital raises could be seen as both a necessity and an opportunity. It’s a chance for Akanda to solidify its market stance amidst global expansion in medical cannabis, provided the market conditions remain favorable and the company executes its strategies effectively.
London, United Kingdom--(Newsfile Corp. - May 17, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 2,491,381 common shares at a purchase price of
Univest Securities LLC is acting as the exclusive financial advisor in connection with the offering.
The gross proceeds to Akanda from this offering were approximately
The securities described above were offered pursuant to an effective shelf registration statement on Form F-3, as amended (File No. 333-276577) previously filed with the Securities and Exchange Commission ("SEC") and was declared effective on January 29, 2024. The securities were offered only by means of the prospectus supplement and the accompanying base prospectus that form a part of the registration statement. The final prospectus supplement and accompanying base prospectus relating to the offering was filed with the SEC on May 17, 2024 and will be available free of charge on the SEC's website at http://sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Akanda Corp.
Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda's portfolio includes CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, one of the first fully digital pain clinics in the UK. Akanda also acquired the right to develop a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company plans to develop THC and cannabinoid (CBD) facilities at this site.
Connect with Akanda: Email | Website | LinkedIn | Twitter | Instagram
Investor Contact
Cautionary Note Regarding Forward-Looking Information and Statements
This press release contains certain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Akanda's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Akanda's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". Forward-looking statements may relate to anticipated events or results including, but not limited to business strategy, product development and sales and growth plans. The forward-looking statements contained in this press release are made as of the date of this press release, and Akanda does not undertake to update any forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209738
FAQ
What was the purpose of Akanda's registered direct offering?
How many common shares did Akanda sell in the offering?
What was the price per share in Akanda's direct offering?
How many pre-funded warrants were issued in Akanda's offering?
What is the exercise price for the pre-funded warrants issued by Akanda?
What was the total gross proceeds raised by Akanda from the offering?
Who acted as the financial advisor for Akanda's offering?
What will Akanda use the proceeds from the offering for?
Where can I find the final prospectus supplement and base prospectus for Akanda's offering?
